Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on March 10, 2003

Hypertension. 2003
Published online before print March 10, 2003, doi: 10.1161/01.HYP.0000061120.23237.D9
A more recent version of this article appeared on April 1, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
41/4/943    most recent
01.HYP.0000061120.23237.D9v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fadl, Y. Y.
Right arrow Articles by Carroll, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fadl, Y. Y.
Right arrow Articles by Carroll, E. R.
Related Collections
Right arrow Lipids
Right arrow Secondary prevention
Right arrow Pathophysiology
Right arrow Risk Factors
Right arrow Other hypertension
Right arrow Fibrinolysis
Right arrow Arterial thrombosis
Right arrow Coagulation
Right arrow Fibrinogen/fibrin
Right arrow Thrombin
Right arrow Coumarins
Right arrow Thrombosis risk factors
Right arrow Clinical Studies
Right arrow Acute myocardial infarction
Right arrow Epidemiology
Right arrow Gene therapy

Submitted on October 10, 2002
Revised on October 25, 2002

History of Hypertension and Enhanced Thrombogenic Activity in Postinfarction Patients

Yazid Y. Fadl; Wojciech Zareba*; Arthur J. Moss; Victor J. Marder; Charles S. Sparks; Luc F. Miller Watelet; and Elizabeth R. Carroll

From the Cardiology Unit, Department of Medicine (Y.Y.F., W.Z., A.J.M., E.R.C.), and the Departments of Pathology (C.S.S.) and Biostatistics (L.F.M.W.), University of Rochester Medical Center, Rochester, NY; and the Vascular Medicine Center, Orthopedic Hospital, UCLA School of Medicine (V.J.M.), Los Angeles, Calif.

* To whom correspondence should be addressed. E-mail: heartwz{at}heart.rochester.edu.

Abstract--Hypertension is a risk factor for coronary thrombosis and death in cardiac patients mediated in part by endothelial damage or dysfunction and increased thrombogenicity. However, there are no data regarding the association between hypertension and thrombogenic activity in stable patients after myocardial infarction and limited data about the prognostic significance of thrombogenic factors in hypertensive patients after infarction. Therefore, levels of thrombogenic, lipid, and inflammatory factors were measured 2 months after an acute myocardial infarction in 461 hypertensive and 582 nonhypertensive patients. Thrombogenic factors included D-dimer, fibrinogen, plasminogen activator inhibitor-1, von Willebrand factor, factor VII, and factor VIIa. Lipid variables included cholesterol (total, HDL, LDL), triglyceride, lipoprotein (a), apolipoprotein-A1, and apolipoprotein-B. The prognostic significance of these factors for predicting cardiac events during a 2-year follow-up was evaluated in hypertensive and nonhypertensive patients. In comparison with nonhypertensive patients, those with hypertension had higher levels of D-dimer (607 versus 453 mg/L, P<0.001), fibrinogen (3.64 versus 3.43 g/L, P<0.001), plasminogen activator inhibitor-1 (29.7 versus 27.3 ng/mL, P=0.01), von Willebrand factor (159 versus 141 IU/dL; P<0.001), and higher levels of inflammatory markers (hsCRP and SAA). In multivariate analysis after adjustment for clinical covariates, elevated D-dimer was the only factor independently associated with a history of hypertension (OR, 1.38, P=0.05). D-Dimer was associated with an increased risk of recurrent cardiac events in both hypertensive (hazard ratio=3.02, P=0.005) and nonhypertensive (hazard ratio=2.42, P=0.02) patients. Thus, patients after infarction with a history of hypertension have enhanced thrombogenic activity, which predisposes them to recurrent cardiac events.


Key words: hypertension, chronic • myocardial infarction • hemostasis • fibrinogen • lipids